贲门癌同步放化疗对比单纯放疗的疗效分析

Comparison of Efficacy of Chemoradiotherapy and Radiotherapy for Cardiac Carcinoma

目的观察希罗达同步放疗治疗贲门癌的临床效果。方法将60例贲门癌患者随机分为实验组和对照组,每组均为30例。实验组患者给予希罗达并同步放疗治疗,其中希罗达的给药剂量按照1 000 mg/m2进行,每天早晚口服1次,连服2周,间隔1周再重复给药;同步进行的放疗为52~54 GY/200 c GY/次,进行6周。对照组患者的放疗同样为52~54 GY/200 c GY/次。观察2组患者的总体治疗有效率,患者的1、2年生存率以及不良反应的发生情况。结果实验组患者的总体治疗有效率为76.67%,显著高于对照组的36.67%(P<0.05);实验组患者的1、2年生存率分别为70.00%、53.33%,均显著高于对照组的43.33%、26.67%(P<0.05)。2组患者的不良反应主要包括胃肠道反应、血液毒性、骨髓抑制等,2组的不良反应均处于一个可耐受状态。结论与单纯放疗相比,希罗达联合同步放疗治疗贲门癌的近期疗效显著,能显著提高患者的1、2年生存率,毒副作用处在一个可耐受的范围。

Objective To observe the clinical efficacy of xeloda chemoradiotherapy for cardiac carcinoma. Methods 60 patients with cardiac carcinoma were randomly divided into the experimental group and the control group,30 cases in each. The experimental group was treated by xeloda and concurrent radiotherapy( 1 000 mg / m2,1 time each day for 2 weeks,a pause after every week) and with 52 ~ 54 GY /200 c GY / time for thoracic radiation therapy,the total effective rates,1-and 2-year survival rates and adverse reactions of the 2 groups were observed. Results The total effective rate of the experimental group( 76. 67%)was significantly higher than that of control group( 36. 67%)( P < 0. 05),and 1-and 2-year survival rates of the experimental group( 70. 00%,53. 33%) were significantly higher than those of the control group( 43. 33%,26. 67%)( P < 0. 05),the main adverse reactions were mainly gastrointestinal reaction,hematotoxicity,myelosuppression,the patients were tolerate to these adverse reactions. Conclusion Xeloda concurrent radiotherapy for cardiac carcinoma is effective,and can improve 1-and 2-year survival rates,the toxic reactions are in a tolerance scale for patients.